Inici › Càncer de pulmó de cèl·lules no petites › Minnesota › Duluth
Assaigs clínics de Càncer de pulmó de cèl·lules no petites a Duluth, MN
13 estudis de Càncer de pulmó de cèl·lules no petites busquen participants en centres de Duluth i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
ReclutantFase 3
- Essentia Health Cancer Center, Duluth
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
ReclutantFase 2
- Essentia Health Cancer Center, Duluth
- Essentia Health Saint Mary's Medical Center, Duluth
- Miller-Dwan Hospital, Duluth
- i 1 més
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
ReclutantFase 3
- Essentia Health Cancer Center, Duluth
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
ReclutantFase 1/2
- St. Luke'S /ID# 273344, Duluth
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
ReclutantFase 3
- Research Site, Duluth
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
ReclutantFase 3
- Clinical Study Sites, Duluth
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
ReclutantFase 3
- Miller-Dwan Hospital, Duluth
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
ReclutantFase 2
- Essentia Health Cancer Center, Duluth
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
ReclutantFase 2
- Essentia Health Cancer Center, Duluth
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
ReclutantFase 2
- Essentia Health Cancer Center, Duluth
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
ReclutantFase 2/3
- Essentia Health Cancer Center, Duluth
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
ReclutantEstudi observacional
- Essentia Health Cancer Center, Duluth
- Saint Luke's Hospital of Duluth, Duluth
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutantEstudi observacional
- Massive Bio SYNERGY-AI site, Duluth
Assaigs de Càncer de pulmó de cèl·lules no petites en altres ciutats
- Houston, TX145 estudis
- New York City, NY120 estudis
- Arlington, VA104 estudis
- Nashville, TN97 estudis
- Boston, MA90 estudis
- Los Angeles, CA87 estudis
- St. Louis, MO73 estudis
- Chicago, IL61 estudis
- Baltimore, MD60 estudis
- San Antonio, TX59 estudis
- Columbus, OH56 estudis
- Washington, DC55 estudis
Altres estudis a Duluth
- Càncer de pulmó11 estudis
- Càncer de pròstata7 estudis
- Càncer de mama7 estudis
- Càncer de còlon6 estudis
- Càncer de bufeta6 estudis
- Leucèmia mieloide aguda6 estudis
- Càncer d'endometri5 estudis
- Càncer d'estómac5 estudis
- Càncer rectal5 estudis
- Càncer d'esòfag5 estudis
- Càncer de laringe5 estudis
- Melanoma5 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.